ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
41 announcements
Sai Parenterals is transitioning from a standalone unit to a consolidated manufacturing and R&D powerhouse through strategic acquisitions. While revenue grew 9% sequentially, high depreciation from new assets is currently masking operating profitability gains.
Sai Parenterals filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoters and promoter group hold 51.16 per cent.
Q2/H1 FY27 deck (Sep 2026) gives no quarterly P&L figures. Highlights: 302 products, 599 registrations, FY26 export share 63%, Saicriti injectable and Noumed acquisitions.
Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196 crore and PAT of Rs. 11 crore. Gross margin improved to 47.5%.
Sai Parenterals will acquire the remaining 25% stake in its 75% subsidiary SP Analytics for cash, making it wholly owned. Related-party approval was taken at the 1 November 2026 board meeting, with completion by 31 December 2026.
Sai Parenterals Ltd reported revenue from operations of ₹194.9 Cr (+264.3% YoY) and net profit of ₹10.5 Cr (+66.7% YoY) for Q2 FY27.
Sai Parenterals Ltd notified a Board Meeting on 1 Nov 2026 to approve unaudited Q2/H1 FY27 results. No financial figures or decisions are reported yet.
Sai Parenterals Limited has acquired a 60% stake in Prathyak Laboratories Private Limited for ₹15 Crore. This acquisition provides an operational R&D facility in Hyderabad.
Sai Parenterals Ltd submitted the Monitoring Agency Report for the quarter ended 30th June 2026 regarding the utilization of IPO proceeds, as per SEBI regulations.
Sai Parenterals Limited appointed Mr. Ashwani Singh Bisht as Company Secretary and Mr. Arvind Gannimitta as COO. These appointments follow the resignation of Ms. Shivali Aggarwal.
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement with an Australian pharmacy chain, valued at approximately ₹204 Crore.
Sai Parenterals Ltd submitted its 25th Annual Report for FY 2025-26 to the stock exchanges as required under SEBI (LODR) regulations.
Sai Parenterals Limited has submitted the notice for its 25th Annual General Meeting, scheduled to be held on 10th September, 2026 via video conference.
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals Limited will acquire a 60% stake in Prathyuk Laboratories Private Limited for ₹15 Crore. This strategic move secures an established R&D setup in the pharma sector.
Sai Parenterals Limited will acquire a 60% equity stake in Saicriti Pharma Private Limited for ₹83.83 Crore in cash.
Sai Parenterals is transitioning from a domestic-focused player to an export-driven CDMO/branded generic platform through major acquisitions and capacity expansion. Q1 FY27 presentation focuses on IPO proceeds variation and global accreditation strategy.
Sai Parenterals announced Q1 FY27 results, reporting standalone revenue of Rs. 56.2 crore. The company also announced acquisitions in Saicriti Pharma and Prathyak Laboratories.
Sai Parenterals Limited announced the appointment of Mr. Kunal Kakumanu as Executive Director, alongside the resignations of Mrs. Aruna Karusala and Ms. Shivali Aggarwal.
Sai Parenterals reported no deviation or variation in the utilization of IPO proceeds for the quarter ended June 30, 2026. This is a routine compliance filing.
Sai Parenterals Ltd reported revenue from operations of ₹178.7 Cr (+435.0% YoY) and net profit of ₹7.9 Cr (+464.3% YoY) for Q1 FY27.
Sai Parenterals has scheduled a board meeting for August 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Sai Parenterals Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulatory requirements.
Sai Parenterals Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, as required by SEBI regulations.
Sai Parenterals Ltd named Aakanksha Dubey & Co. as Secretarial Auditor and NSVR & Associates as Internal Auditor. Sai Krishna & Associates appointed Cost Auditor for 12 months.
Sai Parenterals Ltd announced the appointment of secretarial, internal and cost auditors, and authorised the MD to explore growth opportunities. The board met on 06 July 2026.
Sai Parenterals signed a ₹1,300 Crore OTC medicine supply agreement with Noumed Pharmaceuticals. The contract lasts 7.5 years with extension options.
Sai Parenterals reports transformational FY26 following the Noumed acquisition. Focus shifts from asset building to monetization through vertical integration and expanding the CDMO export business.
Sai Parenterals secured a ₹104.50 Crore exclusive anti-TB product supply contract from Philippines-based PILL CORP. The ten-year agreement provides significant long-term revenue visibility and international market expansion.